The POLAR Study: Pembrolizumab With Olaparib for Metastatic Pancreatic Cancer
By Wungki Park, MD, MS - Last Updated: September 27, 2024Dr. Wungki Park gives an overview of the POLAR study, which examined the use of olaparib with pembrolizumab for patients with metastatic pancreatic cancer.
Advertisement
The study investigated the combination in patients with non-core homologous recombination deficiency, and in those who demonstrated high response to platinum therapy.
Watch the first part of our interview with Dr. Park on the use of ASP3082 for solid tumors here.
Advertisement
Related Posts
Circulating tumor DNA burden in patients with gastric cancer may aid oncologists in determining treatment options.
The phase 3 NEOPAN study has shown that FOLFIRINOX can significantly improve PFS compared with gemcitabine.
Researchers evaluated the use of mFOLFIRINOX for the treatment of patients with resectable pancreatic adenocarcinoma.
Dr. Christopher Lieu shares his top liver-directed therapies for metastatic colorectal cancer with liver involvement.
Dr. Christopher Lieu shares his list of top targeted therapies for metastatic colorectal cancer.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.